Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21198858)

  • 21. [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
    Bai CM; Yang T; Xü Y; Zhang W; Liu XL; Zhu YL; Chen SC; Shen T
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):142-4. PubMed ID: 16750023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
    Troutaud D; Petit B; Bellanger C; Marin B; Gourin-Chaury MP; Petit D; Olivrie A; Feuillard J; Jauberteau MO; Bordessoule D
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):118-24. PubMed ID: 20371444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B
    Semin Hematol; 2006 Oct; 43(4):213-20. PubMed ID: 17027655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary colonic lymphoma: an analysis of 74 cases with localized large-cell lymphoma.
    Tang TC; Kuo MC; Chang H; Dunn P; Wang PN; Wu JH; Lin TL; Hung YS; Kuo TT; Shih LY
    Eur J Haematol; 2011 Jul; 87(1):28-36. PubMed ID: 21535155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
    Visco C; Canal F; Parolini C; Andreoli A; Ambrosetti A; Krampera M; Lestani M; Pizzolo G; Chilosi M
    Haematologica; 2006 May; 91(5):687-90. PubMed ID: 16670073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
    Yoon DH; Choi DR; Ahn HJ; Kim S; Lee DH; Kim SW; Park BH; Yoon SO; Huh J; Lee SW; Suh C
    Eur J Haematol; 2010 Aug; 85(2):149-57. PubMed ID: 20477862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse large B-cell lymphoma with fibrillary matrix.
    Dargent JL; Meiers I; Lespagnard L; Ma Y; Dehou MF; Verhest A
    Diagn Cytopathol; 2002 Oct; 27(4):223-6. PubMed ID: 12357500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Centroblastic diffuse large B cell lymphoma displays distinct expression pattern and prognostic role of apoptosis resistance related proteins.
    Faccion RS; Rezende LM; Romano Sde O; Bigni Rde S; Mendes GL; Maia RC
    Cancer Invest; 2012 Jun; 30(5):404-14. PubMed ID: 22571341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
    Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
    Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S; Ng CP; Bonavida B
    Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
    Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
    Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
    Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.
    Muris JJ; Cillessen SA; Vos W; van Houdt IS; Kummer JA; van Krieken JH; Jiwa NM; Jansen PM; Kluin-Nelemans HC; Ossenkoppele GJ; Gundy C; Meijer CJ; Oudejans JJ
    Blood; 2005 Apr; 105(7):2916-23. PubMed ID: 15576477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype.
    Harris J; Ibrahim H; Amen F; Karadimitris A; Naresh KN; Macdonald DH
    Hematol Oncol; 2012 Mar; 30(1):8-12. PubMed ID: 21638304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type.
    Boelens J; Jais JP; Vanhoecke B; Beck I; Van Melckebeke H; Philippé J; Bracke M; Jardin F; Brière J; Leroy K; Offner F; Lust S
    Leuk Res; 2013 Jan; 37(1):3-8. PubMed ID: 22938940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.